Three-year mortality among men newly diagnosed with metastatic prostate cancer in England fell between 2015 and 2022 in a national analysis covering 45,339 patients. The proportion who died within three years was 55.8 per cent for men diagnosed in 2015 and 47.1 per cent for those diagnosed in 2022.
The findings offer evidence of improving outcomes for men whose cancer had already spread beyond the prostate at diagnosis. They do not mean that metastatic prostate cancer is now curable, nor that every man diagnosed can expect to live for a particular length of time. Nearly half of the men in the 2022 group died within three years.
What the analysis measured
The study examined men newly diagnosed with metastatic hormone-sensitive prostate cancer in England from 2015 to 2022. It drew on national cancer registration data linked with records of deaths and causes of death. Researchers followed patients for three years after diagnosis; the available follow-up ran to 1 July 2025, so the analysis included diagnoses made up to 30 June 2022.
The percentage change is a population-level comparison between groups diagnosed in different years. It is not a prediction for an individual patient, and it does not show that each man’s personal risk changed by the same amount. Across the full cohort, three-year overall mortality declined from 55.8 per cent to 47.1 per cent. Rounded figures are often expressed as 56 per cent and 47 per cent.
Researchers did not have patient-level treatment information for this analysis. Its purpose was to capture the combined effect of changes in care and other circumstances affecting access to diagnosis and treatment. That design can show that outcomes changed across the population, but it cannot isolate how much of the change came from a particular medicine or intervention.
Progress, with important limits
Newer treatment combinations, including chemotherapy and hormone therapies, have been used in care for advanced prostate cancer. Improvements in staging, scans, referral and access to specialist teams may also have influenced outcomes. These are plausible parts of a changing care landscape, rather than causes quantified separately by this study.
The wider national audit also examined a continuing rise in prostate cancer diagnoses. Its 2025 diagnosis counts cover more than 60,800 men in England, seven per cent more than the previous year, including more than 6,300 diagnosed with disease that had spread. Those population-level counts describe the scale of the challenge and are separate from the 2015–2022 survival analysis.
Metastatic disease remains serious and incurable, and the results should not obscure the fact that 47.1 per cent of the 2022 diagnosis group died within three years. Outcomes also vary between individuals. The figures do not establish whether every patient who might benefit from newer treatment received it, or whether the same improvement will continue in future years.
The analysis therefore provides a national measure of change, not a guarantee or a treatment recommendation. Its strongest conclusion is that three-year mortality in the studied population was lower for men diagnosed in 2022 than for men diagnosed seven years earlier. Understanding which elements of care contributed, and how consistently effective treatments reach patients, remains important as diagnosis numbers rise.
